INS and metabolic syndrome: The consequence of AMPK activation is stimulation of hepatic fatty acid oxidation and inhibition of cholesterol and triglyceride synthesis, inhibition of adipocyte lipolysis, stimulation of skeletal muscle fatty acid oxidation and glucose uptake, and modulation of insulin secretion by pancreatic beta-cells; thus, AMPK is an emerging drug target for diabetes and metabolic syndrome [23].